Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Prostate Cancer
Interventions
DRUG

Liposome Entrapped Docetaxel (LE-DT)

110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity

Trial Locations (2)

20007

Georgetown University Medical center, Washington D.C.

97213-2933

Providence Portland Medical center, Portland

Sponsors
All Listed Sponsors
lead

INSYS Therapeutics Inc

INDUSTRY